Table 1.
Distribution of histologic subtype, pathologic diagnosis, demographic, and clinical characteristics of glioma patients from the UCSF Adult Glioma Study.
| N | Percent | Mean age (y) | SE (y) | Median age (y) | |
|---|---|---|---|---|---|
| All Cases | 270 | 100.0% | 42.2 | 0.7 | 41.0 |
| Histology | |||||
| Astrocytoma | 113 | 41.9% | 42.4 | 1.3 | 41.0 |
| Oligodendroglioma | 104 | 38.5% | 44.5 | 1.0 | 44.5 |
| Oligoastrocytoma | 53 | 19.6% | 36.9 | 1.3 | 36.0 |
| Pathology | |||||
| Diffuse astrocytoma (A-II) | 49 | 18.2% | 41.4 | 1.9 | 40.0 |
| Anaplastic astrocytoma (A-III) | 64 | 23.7% | 43.2 | 1.8 | 41.5 |
| Oligodendroglioma (O-II) | 80 | 29.6% | 43.9 | 1.2 | 44.0 |
| Anaplastic oligodendroglioma (O-III) | 24 | 8.9% | 46.8 | 2.0 | 51.0 |
| Oligoastrocytoma (OA-II) | 42 | 15.6% | 37.7 | 1.6 | 36.0 |
| Anaplastic oligoastrocytoma (OA-III) | 11 | 4.1% | 34.1 | 2.4 | 32.0 |
| Gender | |||||
| Male | 147 | 54.4% | |||
| Female | 123 | 45.6% | |||
| Surgery | |||||
| Biopsy | 20 | 7.4% | |||
| Resection | 250 | 92.6% | |||
| Adjunct therapy | |||||
| Chemotherapy | |||||
| No | 107 | 40.7% | |||
| Yes | 154 | 58.6% | |||
| Unknown | 2 | 0.8% | |||
| Temozolomide | 129 | 47.8% | |||
| Radiotherapy | |||||
| No | 127 | 47.0% | |||
| Yes | 143 | 53.0% | |||
| Outcome | |||||
| Alive | 165 | 61.1% | |||
| Dead | 105 | 38.9% |